Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

2.190 -0.295 (-11.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bioAffinity Technologies, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
EQNX::TICKER_START (NASDAQ:INBS),(NASDAQ:CDIO),(NASDAQ:BIAF),(NASDAQ:TRIB),(NASDAQ:SOBR) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Cannabis Death
News headline image
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
From FN Media Group LLC
Via GlobeNewswire
News headline image
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
News headline image
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Set for Continued Expansion in 2025
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Are Pharma Stocks Harmful To Your Financial Health ? ↗
It seems time for the Securities and Exchange Commission to oversee stock advertising and consider a ban, or at least a danger warning label. 
Via Talk Markets
News headline image
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q2 2024 ↗
bioAffinity Technologies just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.